Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases

Bibliography

• Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 2011;5:1613-21
   PubMedGoogle Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111(3):491-500; discussion 00
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs 2011;16(2):309-22
   PubMed Web of Science ®Google Scholar
• Liu B, Sen HN, Nussenblatt R. Susceptibility genes and pharmacogenetics in ocular inflammatory disorders. Ocul Immunol Inflamm 2012;20(5):315-23
   PubMed Web of Science ®Google Scholar
• Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005;60(2):207-25
   PubMed Web of Science ®Google Scholar
• Shichi H, Nebert DW. Genetic differences in drug metabolism associated with ocular toxicity. Environ Health Perspect 1982;44:107-17
   PubMed Web of Science ®Google Scholar
• Levinson RD. Immunogenetics of ocular inflammatory disease. Tissue Antigens 2007;69(2):105-12
   PubMed Web of Science ®Google Scholar
• Brewerton DA, Caffrey M, Nicholls A, et al. Acute anterior uveitis and HL-A 27. Lancet 1973;302(7836):994-6
   PubMedGoogle Scholar
• Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973;1(7809):904-7
   PubMed Web of Science ®Google Scholar
• Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol 2005;50(6):519-41
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94(2):147-58
   PubMed Web of Science ®Google Scholar
• Levinson RD, Park MS, Rikkers SM, et al. Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 2003;44(2):653-7
   PubMed Web of Science ®Google Scholar
• Al-Mutawa SA, Hegab SM. Behcet's disease. Clin Exp Med 2004;4(3):103-31
   PubMed Web of Science ®Google Scholar
• Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behcet's disease. Cell Mol Life Sci 2003;60(9):1903-22
   PubMed Web of Science ®Google Scholar
• Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol 2005;20(3):183-90
   PubMedGoogle Scholar
• Zeggini E, Packham J, Donn R, et al. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology (Oxford) 2006;45(8):972-4
   PubMed Web of Science ®Google Scholar
• Giannini EH, Malagon CN, Van Kerckhove C, et al. Longitudinal analysis of HLA associated risks for iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol 1991;18(9):1394-7
   PubMed Web of Science ®Google Scholar
• Levinson RD, See RF, Rajalingam R, et al. HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt-Koyanagi-Harada's disease in Southern California. Hum Immunol 2004;65(12):1477-82
   PubMed Web of Science ®Google Scholar
• Yanagimachi M, Miyamae T, Naruto T, et al. Association of HLA-A*02:06 and HLA-DRB1*04:05 with clinical subtypes of juvenile idiopathic arthritis. J Hum Genet 2011;56(3):196-9
   PubMed Web of Science ®Google Scholar
• Martin TM, Rosenbaum JT. Genetics in uveitis. Int Ophthalmol Clin 2005;45(2):15-30
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492-513
   PubMed Web of Science ®Google Scholar
• De Iudicibus S, Franca R, Martelossi S, et al. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011;17(9):1095-108
   PubMed Web of Science ®Google Scholar
• Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann NY Acad Sci 2009;1179:179-98
   PubMed Web of Science ®Google Scholar
• Hawkins GA, Peters SP. Pharmacogenetics of asthma. Methods Mol Biol 2008;448:359-78
   PubMedGoogle Scholar
• Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics 2010;11(3):421-37
   PubMed Web of Science ®Google Scholar
• Gerzenstein SM, Pletcher MT, Cervino AC, et al. Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide. Ophthalmic Genet 2008;29(4):166-70
   PubMed Web of Science ®Google Scholar
• Fingert JH, Alward WL, Wang K, et al. Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. Mol Vis 2010;16:596-601
   PubMed Web of Science ®Google Scholar
• Creed TJ, Lee RW, Newcomb PV, et al. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol 2009;183(1):164-71
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32(2):362-5
   PubMed Web of Science ®Google Scholar
• Ranganathan P. The challenges of methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2012;13(4):377
   PubMed Web of Science ®Google Scholar
• Ranganathan P. Genetic and nongenetic determinants of MTX efficacy in RA. Pharmacogenomics 2012;13(4):378
   Web of Science ®Google Scholar
• Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 2010;30(2):101-8
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149(3):423-32; e1-2
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006;244(7):788-94
   PubMed Web of Science ®Google Scholar
• Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005;80(2 Suppl):S265-71
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Arienti S, Rampudda M, et al. Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann NY Acad Sci 2007;1110:516-24
   PubMed Web of Science ®Google Scholar
• Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010;11(3):369-90
   PubMed Web of Science ®Google Scholar
• Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009;19(8):626-34
   PubMed Web of Science ®Google Scholar
• Zhao W, Fakhoury M, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010;50(11):1280-91
   PubMed Web of Science ®Google Scholar
• Gensburger O, Van Schaik RH, Picard N, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics 2010;20(9):537-43
   PubMed Web of Science ®Google Scholar
• Pazik J, Oldak M, Dabrowski M, et al. Association of UDP-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function. Ann Transplant 2011;16(4):69-73
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009 Oct;148(4):500-9; e2
   PubMed Web of Science ®Google Scholar
• Calin A. A placebo controlled, crossover study of azathioprine in Reiter's syndrome. Ann Rheum Dis 1986;45(8):653-5
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Eng J Med 1984;311(24):1528-33
   PubMed Web of Science ®Google Scholar
• Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126(8):608-14
   PubMed Web of Science ®Google Scholar
• Tai HL, Krynetski EY, Schuetz EG, et al. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proce Nat Acad Sci USA 1997;94(12):6444-9
   PubMed Web of Science ®Google Scholar
• Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am J Hum Genet 1996;58(4):694-702
   PubMed Web of Science ®Google Scholar
• McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics 2002;3(1):89-98
   PubMed Web of Science ®Google Scholar
• Santoro A, Felipe CR, Tedesco-Silva H, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 2011;12(9):1293-303
   PubMed Web of Science ®Google Scholar
• Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998;30(4):1573-9
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96(3):275-82
   PubMed Web of Science ®Google Scholar
• Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005;13(4):289-93
   PubMed Web of Science ®Google Scholar
• Araujo AA, Wells AP, Dick AD, Forrester JV. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000;84(9):979-82
   PubMed Web of Science ®Google Scholar
• Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118(6):723-9
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998;6(2):101-9
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115(6):763-9
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106(4):723-8
   PubMed Web of Science ®Google Scholar
• Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001;12(2):368-73
   PubMed Web of Science ®Google Scholar
• Jordan de Luna C, Herrero Cervera MJ, Sanchez Lazaro I, et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Transplant Proc 2011;43(6):2241-3
   PubMed Web of Science ®Google Scholar
• Zhu H, Ge W. Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients. Pharmacogenomics 2011;12(11):1505-8
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010;32(4):387-93
   PubMed Web of Science ®Google Scholar
• Macphee IA. Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit 2010;32(3):261-4
   PubMed Web of Science ®Google Scholar
• Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004;3(9):739-48
   PubMed Web of Science ®Google Scholar
• Provenzani A, Notarbartolo M, Labbozzetta M, et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009;14(1):23-31
   PubMed Web of Science ®Google Scholar
• Tang HL, Ma LL, Xie HG, et al. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet Genomics 2010;20(9):525-31
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009;20(6):1404-15
   PubMed Web of Science ®Google Scholar
• Buckley CE III, Gills JP Jr. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969;124(1):29-35
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76(4):241-3
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994;21(1):123-5
   PubMed Web of Science ®Google Scholar
• Elliott JH, Ballinger WH. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-81
   PubMedGoogle Scholar
• O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984;76(1):75-84
   PubMed Web of Science ®Google Scholar
• Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990;74(6):353-7
   PubMed Web of Science ®Google Scholar
• Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304(8):441-7
   PubMed Web of Science ®Google Scholar
• Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38(8):1120-7
   PubMed Web of Science ®Google Scholar
• Klippel JH, Austin HA III, Balow JE, et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am 1987;13(1):47-56
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116(6):488-98
   PubMed Web of Science ®Google Scholar
• Gonzalez-Neira A. Pharmacogenetics of chemotherapy efficacy in breast cancer. Pharmacogenomics 2012;13(6):677-90
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010;102(6):1003-9
   PubMed Web of Science ®Google Scholar
• Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53(23):5629-37
   PubMed Web of Science ®Google Scholar
• Gor PP, Su HI, Gray RJ, et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010;12(3):R26
   PubMed Web of Science ®Google Scholar
• Heo J, Sepah YJ, Yohannan J, et al. The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther 2012;12(8):995-1008
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127(6):819-22
   PubMed Web of Science ®Google Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004;22(4 Suppl 34):S14-16
   PubMed Web of Science ®Google Scholar
• Yeh S, Albini TA, Moshfeghi AA, Nussenblatt RB. Uveitis, the comparison of age-related macular degeneration treatments trials (CATT), and intravitreal biologics for ocular inflammation. Am J Ophthalmol 2012;154(3):429-35; e2
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8
   PubMed Web of Science ®Google Scholar
• Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003;30(12):2557-62
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Nat Acad Sci USA 1999;96(13):7462-6
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008;31(2):91-7
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007;91(2):263-4
   PubMed Web of Science ®Google Scholar
• Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84(1):107-9
   PubMed Web of Science ®Google Scholar
• Lacruz-Guzman D, Torres-Moreno D, Pedrero F, et al. Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. Eur J Clin Pharmacol 2013;69(3):431-8
   PubMed Web of Science ®Google Scholar
• Morales-Lara MJ, Canete JD, Torres-Moreno D, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012;79(6):591-6
   PubMed Web of Science ®Google Scholar